{
    "Trade/Device Name(s)": [
        "cobas\u00ae Cdiff Nucleic acid test for use on the cobas\u00ae Liat\u00ae System"
    ],
    "Submitter Information": "Roche Molecular Systems, Inc.",
    "510(k) Number": "K171770",
    "Predicate Device Reference 510(k) Number(s)": [
        "K142422"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OZN",
        "OOI"
    ],
    "Summary Letter Date": "September 12, 2017",
    "Summary Letter Received Date": "June 14, 2017",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3130",
        "21 CFR 862.2570"
    ],
    "Regulation Name(s)": [
        "Clostridium difficile toxin gene amplification assay",
        "Real Time Nucleic Acid Amplification System"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "genetic molecular"
    ],
    "Analyte(s)": [
        "Clostridium difficile toxin B (tcdB) gene"
    ],
    "Specimen Type(s)": [
        "Unformed (liquid or soft) stool specimens"
    ],
    "Specimen Container(s)": [
        "cobas\u00ae PCR Media Uni Swab Sample Kit"
    ],
    "Instrument(s)/Platform(s)": [
        "cobas\u00ae Liat\u00ae System",
        "cobas\u00ae Liat\u00ae Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Real-time PCR",
        "Silica magnetic particle-based nucleic acid extraction",
        "TaqMan probe-based real-time PCR amplification and detection"
    ],
    "Methodologies": [
        "Nucleic acid extraction",
        "Real-time PCR",
        "Molecular amplification"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay",
        "Tube",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for cobas\u00ae Cdiff nucleic acid test on cobas\u00ae Liat\u00ae System for qualitative detection of C. difficile tcdB gene in stool specimens using real-time PCR",
    "Indications for Use Summary": "Automated, qualitative in vitro diagnostic test using real-time PCR to detect the toxin B (tcdB) gene of toxigenic Clostridium difficile in unformed stool specimens from patients suspected of C. difficile infection, as an aid in diagnosis of CDI in conjunction with clinical and epidemiological risk factors",
    "fda_folder": "Microbiology"
}